NEW YORK, Aug 15 - GlaxoSmithKline has agreed to a multi-year, non-exclusive sublicense to Lexicon Genetic’s gene targeting technologies, Lexicon said Wednesday.
The deal brings the total number of licensees for the technologies to 15.
Under the terms of the agreement, GlaxoSmithKline will pay a one-time fee of an undisclosed amount.
Lexicon Genetics of The Woodlands, Texas, uses gene knockout technology to identify genes of medical interest. In addition to licensing the technology, the company is also using it to develop its own drug discovery efforts.
Lexicon also sells subscriptions to its LexVision database of mouse gene-knockout data, which includes physiological data such as measurements of whole blood-cell count, X-rays, MRI and CT scans, and certain neurological tests.
Last week, Lexicon announced that Bristol-Myers Squibb had chosen certain drug targets from LexVision to move into drug development. The announcement marked the first time one of Lexicon’s database subscribers had identified particularly promising drug targets.